Free Trial

Global Cord Blood (CORBF) Competitors

$1.55 -0.01 (-0.64%)
As of 08/22/2025 09:40 AM Eastern

CORBF vs. FLGT, CDNA, CSTL, AGL, INNV, AUNA, SBC, TALK, PSNL, and EHAB

Should you be buying Global Cord Blood stock or one of its competitors? The main competitors of Global Cord Blood include Fulgent Genetics (FLGT), CareDx (CDNA), Castle Biosciences (CSTL), Agilon Health (AGL), InnovAge (INNV), Auna (AUNA), SBC Medical Group (SBC), Talkspace (TALK), Personalis (PSNL), and Enhabit (EHAB). These companies are all part of the "healthcare" industry.

Global Cord Blood vs. Its Competitors

Global Cord Blood (NYSE:CORBF) and Fulgent Genetics (NASDAQ:FLGT) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations and risk.

In the previous week, Fulgent Genetics had 1 more articles in the media than Global Cord Blood. MarketBeat recorded 1 mentions for Fulgent Genetics and 0 mentions for Global Cord Blood. Fulgent Genetics' average media sentiment score of 1.67 beat Global Cord Blood's score of 0.00 indicating that Fulgent Genetics is being referred to more favorably in the news media.

Company Overall Sentiment
Global Cord Blood Neutral
Fulgent Genetics Very Positive

48.1% of Fulgent Genetics shares are held by institutional investors. 0.5% of Global Cord Blood shares are held by insiders. Comparatively, 31.8% of Fulgent Genetics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Global Cord Blood has a net margin of 0.00% compared to Fulgent Genetics' net margin of -16.83%. Global Cord Blood's return on equity of 0.00% beat Fulgent Genetics' return on equity.

Company Net Margins Return on Equity Return on Assets
Global Cord BloodN/A N/A N/A
Fulgent Genetics -16.83%-2.26%-2.10%

Global Cord Blood has higher earnings, but lower revenue than Fulgent Genetics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Global Cord Blood$196.12M0.96$79.04MN/AN/A
Fulgent Genetics$283.47M2.35-$42.71M-$1.66-13.11

Fulgent Genetics has a consensus target price of $25.33, indicating a potential upside of 16.37%. Given Fulgent Genetics' stronger consensus rating and higher possible upside, analysts plainly believe Fulgent Genetics is more favorable than Global Cord Blood.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Global Cord Blood
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Fulgent Genetics
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67

Global Cord Blood has a beta of -0.6, indicating that its stock price is 160% less volatile than the S&P 500. Comparatively, Fulgent Genetics has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500.

Summary

Fulgent Genetics beats Global Cord Blood on 10 of the 14 factors compared between the two stocks.

Get Global Cord Blood News Delivered to You Automatically

Sign up to receive the latest news and ratings for CORBF and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CORBF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CORBF vs. The Competition

MetricGlobal Cord Bloodhealth & allied services, not elsewhere classified IndustryMedical SectorNYSE Exchange
Market Cap$188.40M$133.89M$5.76B$20.92B
Dividend YieldN/AN/A4.41%3.58%
P/E RatioN/A1.2231.1029.13
Price / Sales0.960.60433.4553.00
Price / Cash1.402.8037.7323.54
Price / BookN/A0.259.535.45
Net Income$79.04M$43.11M$3.26B$992.10M
7 Day PerformanceN/A120.20%2.10%2.61%
1 Month Performance181.82%122.82%2.81%1.46%
1 Year Performance53.47%102.44%30.56%10.72%

Global Cord Blood Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CORBF
Global Cord Blood
N/A$1.55
-0.6%
N/A+53.5%$188.40M$196.12M0.001,200Gap Up
FLGT
Fulgent Genetics
3.6985 of 5 stars
$21.57
+0.2%
$25.33
+17.4%
-5.6%$658.71M$283.47M-12.991,313Positive News
CDNA
CareDx
4.3227 of 5 stars
$11.57
-2.4%
$27.67
+139.1%
-58.1%$630.74M$333.79M11.34740Positive News
CSTL
Castle Biosciences
2.7215 of 5 stars
$19.90
-3.2%
$37.00
+85.9%
-24.3%$596.40M$346.27M-56.86540Positive News
AGL
Agilon Health
2.6997 of 5 stars
$1.25
+1.2%
$3.58
+187.4%
-70.5%$509.74M$6.06B-1.621,076Analyst Forecast
INNV
InnovAge
2.1035 of 5 stars
$3.52
-0.3%
$5.00
+42.0%
-38.4%$476.60M$831.68M-15.302,350
AUNA
Auna
4.3623 of 5 stars
$6.31
+1.0%
$10.70
+69.7%
-17.7%$461.84M$4.35B10.8714,842News Coverage
Earnings Report
Analyst Upgrade
SBC
SBC Medical Group
N/A$4.09
-3.5%
N/AN/A$439.31M$205.42M12.78N/ANews Coverage
Analyst Revision
TALK
Talkspace
3.7872 of 5 stars
$2.57
-1.2%
$4.50
+75.1%
+64.7%$435.41M$202.61M128.56500
PSNL
Personalis
4.0899 of 5 stars
$4.53
-6.6%
$7.42
+63.7%
-15.4%$430.08M$84.61M-3.54400News Coverage
EHAB
Enhabit
1.2476 of 5 stars
$8.03
+0.7%
$8.67
+8.0%
+1.9%$404M$1.03B-3.0110,700

Related Companies and Tools


This page (NYSE:CORBF) was last updated on 8/23/2025 by MarketBeat.com Staff
From Our Partners